Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR TD-9855

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for TD-9855

Subscribe to access the full database, or Sign up for a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01458340 ↗	A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)	Completed	Theravance Biopharma	Phase 2	The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
NCT01458340 ↗	A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)	Completed	Theravance Biopharma R & D, Inc.	Phase 2	The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
NCT01693692 ↗	Phase 2 Study of TD-9855 to Treat Fibromyalgia	Completed	Theravance Biopharma	Phase 2	The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
NCT01693692 ↗	Phase 2 Study of TD-9855 to Treat Fibromyalgia	Completed	Theravance Biopharma R & D, Inc.	Phase 2	The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
NCT01924143 ↗	TD-9855 Mass Balance Study	Completed	Theravance Biopharma	Phase 1	The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]TD-9855
NCT01924143 ↗	TD-9855 Mass Balance Study	Completed	Theravance Biopharma R & D, Inc.	Phase 1	The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]TD-9855
NCT02705755 ↗	TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)	Completed	Theravance Biopharma	Phase 2	This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic orthostatic hypotension to evaluate the effect of TD-9855 in improving symptoms of orthostatic intolerance.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for TD-9855

Condition Name

Chart
Table

Condition Name for
Intervention	Trials
Symptomatic Neurogenic Orthostatic Hypotension	3
ADHD	2
Fibromyalgia	2
Parkinson Disease	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for
Intervention	Trials
Pure Autonomic Failure	4
Hypotension, Orthostatic	4
Hypotension	4
Myofascial Pain Syndromes	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for TD-9855

Trials by Country

Map
Table

Trials by Country for
Location	Trials
United States	89
United Kingdom	10
Australia	10
Spain	9
Canada	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for
Location	Trials
Tennessee	6
New York	6
Florida	6
California	5
Washington	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for TD-9855

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	3
Phase 1	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	7
Active, not recruiting	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TD-9855

Sponsor Name

Chart
Table

Sponsor Name for
Sponsor	Trials
Theravance Biopharma	9
Theravance Biopharma R & D, Inc.	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for
Sponsor	Trials
Industry	13
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys

Harvard Business School

Colorcon

AstraZeneca

Medtronic

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.